The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved 847 parallel import licences in 2026, demonstrating continued reliance on cross-border pharmaceutical sourcing to mitigate domestic supply constraints. This regulatory mechanism permits licensed importers to source medicines from other European markets where products are legally approved, creating an essential safety valve for the UK healthcare system during periods of shortage.
Parallel importation represents a pragmatic solution that bridges supply gaps without compromising patient safety. All imported medicines undergo rigorous quality assurance protocols equivalent to those applied to domestically supplied products, ensuring therapeutic equivalence and regulatory compliance. This approach reflects international best practices endorsed by the WHO, enabling healthcare systems to maintain continuity of patient care during supply disruptions.
The sustained volume of licences granted underscores systemic challenges in pharmaceutical supply chains and the importance of regulatory flexibility in safeguarding medicine accessibility across the United Kingdom.
Was this article helpful?
